exosom
small
membran
vesicl
secret
multitud
cell
type
exosom
deriv
dendrit
cell
dex
tumor
cell
tex
malign
effus
demonstr
immunomodulatori
function
even
clinic
trial
cancer
treatment
studi
report
phase
clinic
trial
ascitesderiv
exosom
aex
combin
granulocytemacrophag
colonystimul
factor
gmcsf
immunotherapi
colorect
cancer
crc
aex
isol
sucros
densiti
gradient
ultracentrifug
vesicl
contain
divers
immunomodulatori
marker
exosom
tumorassoci
carcinoembryon
antigen
cea
total
patient
cea
advanc
crc
enrol
studi
randomli
assign
treatment
aex
alon
aex
plu
gmcsf
patient
group
receiv
total
four
subcutan
immun
weekli
interv
found
therapi
safe
well
toler
aex
plu
gmcsf
aex
alon
induc
benefici
tumorspecif
antitumor
cytotox
lymphocyt
ctl
respons
therefor
studi
suggest
immunotherapi
crc
aex
combin
gmcsf
feasibl
safe
thu
serv
altern
choic
immunotherapi
advanc
crc
exosom
type
small
vesicl
secret
mani
type
cell
includ
dendrit
cell
dc
tumor
cell
shown
exosom
highli
enrich
major
histocompat
complex
mhc
class
ii
molecul
mhc
class
heat
shock
protein
hsp
adhes
molecul
function
cellular
compon
exosom
produc
numer
cell
type
defin
three
major
criteria
size
nm
diamet
densiti
gdl
sucros
gradient
endocyt
origin
demonstr
previous
exosom
play
function
role
erad
obsolet
protein
antigen
present
act
trojan
hors
virus
prion
recent
exosom
focu
immunologist
exosom
deriv
either
dc
dex
tumor
cell
tex
serv
kind
cellfre
vaccin
induc
potent
antitumor
immun
anim
model
dex
abl
present
antigen
cell
directli
indirectli
stimul
antigenspecif
tcell
respons
use
tumor
vaccin
dex
load
acidelut
tumor
peptid
erad
establish
tumor
mice
tumor
cell
constitut
releas
exosom
tex
extracellular
milieu
mice
reveal
tex
also
serv
antigen
deliveri
system
prevent
autolog
tumor
develop
celldepend
manner
howev
isol
autolog
tex
may
requir
vitro
cultur
primari
tumor
cell
deriv
cancer
patient
may
inconveni
clinic
trial
find
andr
et
al
suggest
exosom
isol
malign
effus
melanoma
patient
deliv
melanoma
antigen
recogn
cell
tumor
antigen
dc
cross
present
specif
cytotox
lymphocyt
ctl
recent
exosom
deriv
malign
effus
cancer
patient
also
prepar
readi
clinic
trial
thu
aex
may
use
cellfre
tumor
vaccin
immunotherapi
cancer
dex
test
safeti
effici
clinic
trial
patient
metastat
melanoma
advanc
nonsmal
cell
lung
cancer
suggest
dex
deriv
good
manufactur
procedur
gmp
grade
safe
feasibl
effici
induct
antigenspecif
tcell
respons
moreov
oligodeoxynucleotid
cpg
doublestrand
rna
lipopolysaccharid
use
adjuv
dexmedi
immunotherapi
previous
other
demonstr
tex
modifi
superantigen
tex
isol
heat
stress
elicit
potent
antitumor
immun
mice
model
extens
demonstr
granulocytemacrophag
american
societi
gene
therapi
phase
clinic
trial
aex
plu
gmcsf
colonystimul
factor
gmcsf
use
adjuv
significantli
increas
effici
antitumor
immun
induct
therefor
evalu
whether
ascitesderiv
exosom
aex
combin
gmcsf
aex
plu
gmcsf
consid
promis
vaccin
cancer
immunotherapi
find
aex
deriv
colorect
cancer
crc
patient
combin
gmcsf
effici
induc
potent
carcinoembryon
antigen
cea
specif
antitumor
immun
advanc
crc
patient
suggest
aex
plu
gmcsf
serv
choic
clinic
immunotherapi
crc
januari
februari
total
crc
patient
elig
accord
enrol
criteria
forti
patient
seventeen
femal
twentythre
male
assess
advanc
crc
patholog
diagnos
stage
iii
iv
per
american
joint
committe
cancer
match
criteria
eg
hlaa
cea
malign
effus
enrol
trial
patient
randomli
assign
treatment
autolog
aex
alon
group
ad
correspond
dose
respect
alex
group
eh
correspond
dose
respect
plu
gmcsf
tabl
treatment
schedul
advers
event
record
first
vaccin
also
antitumor
immun
respons
evalu
week
last
vaccin
accord
method
previous
describ
navabi
andr
exosom
success
prepar
malign
ascit
enrol
crc
patient
hlaa
cea
sucros
gradient
ultracentrifug
examin
isol
product
perform
electron
microscopi
western
blot
confirm
morpholog
protein
compon
found
isol
aex
univers
membran
vesicl
diamet
nm
figur
western
blot
analysi
demonstr
aex
enrich
mhc
molecul
mhci
mhcii
hsp
includ
figur
notabl
typic
cea
crc
also
detect
aex
capac
exosom
stimul
antitumor
immun
respons
larg
depend
level
mhc
molecul
hsp
examin
express
mhci
qualiti
control
standard
aex
prepar
prepar
autolog
aex
contain
high
level
mhci
figur
result
morpholog
densiti
protein
compon
suggest
aex
prepar
us
exosom
gener
therapi
safe
well
toler
total
advers
event
record
throughout
treatment
group
tabl
frequent
report
advers
event
causal
relat
use
aex
aex
plu
gmcsf
mild
grade
sever
includ
inject
site
reaction
event
group
ad
event
group
eh
includ
erythema
pruritu
pain
fever
patient
nausea
patient
fatigu
patient
tabl
signific
hepat
renal
pulmonari
cardiac
hematolog
neurolog
toxic
attribut
treatment
clinic
manifest
autoimmun
reaction
observ
signific
chang
temperatur
blood
pressur
record
last
immun
statu
crc
patient
follow
detect
therapeut
respons
observ
group
ad
treat
aex
per
vaccin
alon
howev
one
case
stabl
diseas
patient
treat
aex
plu
gmcsf
one
case
minor
respons
patient
treat
aex
plu
gmcsf
observ
aex
plu
gmcsf
group
data
shown
previous
shown
dex
tex
aex
induc
antigenspecif
tcell
respons
tumor
growth
regress
result
indic
aex
contain
plenti
immun
molecul
well
cea
aex
plu
gmcsf
treatment
could
improv
clinic
outcom
crc
patient
extent
therefor
went
examin
whether
immunotherapi
aex
aex
plu
gmcsf
induc
system
antigenspecif
antitumor
immun
vitro
vivo
first
perform
antigen
recal
experi
examin
delayedtyp
hypersensit
dth
respons
crc
patient
week
last
immun
found
aex
immun
dose
could
effici
induc
dth
respons
group
c
g
h
presenc
absenc
gmcsf
adjuv
tabl
howev
lower
dose
aex
per
immun
use
gmcsf
could
significantli
increas
effici
aex
induct
dth
evidenc
differ
dth
respons
rate
group
b
group
f
determin
whether
antitumor
immun
respons
specif
crc
examin
ctl
respons
tetram
stain
releas
assay
cytotox
assay
isol
cell
dth
respons
site
hlaa
cea
peptid
ylsganlnl
irrelev
hlaa
coronaviru
sarscov
spike
protein
peptid
rlnevaknl
use
assay
evalu
tetram
test
establish
ratio
percentag
tetram
cell
specif
specif
twofold
posit
one
abbrevi
aex
ascitesderiv
exosom
ajcc
american
joint
committe
cancer
f
femal
gmcsf
granulocytemacrophag
colonystimul
factor
ln
lymph
node
male
surg
surgeri
stand
regimen
oxaliplatin
mgm
iv
day
leucovorin
mgm
iv
day
mgm
iv
day
mgm
continu
infus
ci
day
regimen
repeat
everi
week
b
deg
stand
degramont
regimen
leucovorin
mgm
iv
day
mgm
iv
day
plu
mgm
via
ci
day
regimen
repeat
everi
week
c
stand
regimen
oxaliplatin
mgm
iv
day
leucovorin
mgm
iv
day
mgm
iv
plu
mgm
bolu
day
mgm
via
ci
hour
regimen
repeat
everi
week
f
stand
folfiri
regimen
douillard
irinotecan
mgm
iv
day
leucovorin
mgm
iv
day
mgm
iv
day
plu
mgm
via
ci
hour
day
regimen
repeat
everi
week
e
xelox
regimen
oxaliplatin
mgm
iv
day
capecitabin
mgm
po
bid
total
dose
mgm
day
day
regimen
repeat
everi
week
f
capecitabin
regimen
capecitabin
mgm
po
bid
total
dose
mgm
day
day
regimen
repeat
everi
week
g
aio
regimen
leucovorin
mgm
iv
per
week
mgm
ci
per
week
regimen
repeat
everi
week
abbrevi
aex
ascitesderiv
exosom
gmcsf
granulocytemacrophag
colonystimul
factor
advers
event
record
day
first
immun
week
last
immun
b
toxic
assess
throughout
studi
use
nation
cancer
institut
common
toxic
criteria
version
c
total
advers
event
aextreat
group
summar
present
total
advers
event
aex
gmcsftreat
group
summar
present
abbrevi
aex
ascitesderiv
exosom
ctl
cytotox
lymphocyt
dth
delayedtyp
hypersensit
gmcsf
granulocytemacrophag
colonystimul
factor
interferon
nd
determin
result
present
mean
percentag
tetram
cell
total
emigr
cell
b
cytotox
evalu
effector
dth
sitederiv
cultur
cell
target
cell
ratio
result
present
mean
percentag
cell
lysi
cytotox
lovo
cell
use
control
present
mean
percentag
cell
lysi
parenthes
c
lymphocyt
deriv
dth
sitederiv
cultur
cell
cocultur
cell
cell
parenthes
hour
cocultur
supernat
measur
enzymelink
immunosorb
assay
present
mean
level
dth
respons
treatment
baselin
week
treatment
posttreat
autolog
aex
evalu
result
present
diamet
millimet
respons
site
found
aex
alon
dose
could
effici
induc
hlaa
ctl
product
test
patient
posit
gmcsf
combin
could
significantli
aex
group
versu
aex
plu
gmcsf
group
p
promot
ctl
product
test
patient
posit
tabl
examin
ctl
toxic
crc
use
cell
cea
lovo
cell
cea
target
establish
ratio
percentag
specif
lysi
lovo
twofold
posit
one
found
aex
alon
aex
plu
gmcsf
treatment
could
effici
induc
aexspecif
ctl
toxic
tabl
howev
gmcsf
could
promot
induct
ctl
cytotox
aex
figur
tabl
evalu
releas
use
cell
stimul
cell
neg
control
found
aex
alon
aex
plu
gmcsf
treatment
could
effici
induc
cea
peptid
specif
releas
lymphocyt
figur
tabl
therefor
gener
gmcsf
could
effici
promot
induct
ceaspecif
ctl
product
data
suggest
aex
plu
gmcsf
treatment
effici
aex
alon
induct
tumor
antigen
cea
specif
ctl
respons
may
favor
benefici
clinic
outcom
crc
patient
crc
one
common
gastrointestin
diseas
encount
clinic
practic
malign
ascit
may
present
crc
cell
metastas
seed
periton
caviti
patient
malign
ascit
alway
correl
poor
prognosi
clinic
practic
howev
isol
exosom
contain
effus
induct
antitumor
immun
respons
aex
may
benefici
clinic
therapi
crc
patient
ascit
immunotherapi
crc
malign
ascit
perform
clinic
trial
studi
assess
feasibl
safeti
effici
aex
plu
gmcsf
treatment
crc
demonstr
aex
plu
gmcsf
treatment
effici
aex
alon
induct
tumorspecif
system
antitumor
immun
ctl
respons
treatment
protocol
test
studi
caus
grade
ii
toxic
crc
patient
suggest
success
isol
aex
safe
appli
clinic
trial
therefor
phase
clinic
trial
data
suggest
aex
crc
patient
select
induc
antitumor
immun
presenc
gmcsf
adjuv
significantli
promot
effici
vaccin
aex
show
studi
aex
contain
cea
mhc
molecul
hsp
may
recogn
epiderm
antigenpres
cell
turn
stimul
activ
lymphocyt
vivo
dth
test
confirm
aex
alon
suffici
induct
system
antiaex
immun
suggest
aex
alon
immunogen
detect
ctl
respons
dth
sitesderiv
cultur
cell
indic
aex
activ
ctl
may
elicit
tumor
antigen
eg
cea
specif
antitumor
immun
howev
surpris
aex
alon
even
dose
rather
ineffici
induct
tumorspecif
ctl
respons
may
due
poor
immunogenec
tex
dex
tex
explor
cancer
vaccin
studi
show
tex
dex
effici
induct
tumorspecif
immun
regress
tumor
progress
although
peptid
specif
cytotox
evalu
cr
releas
assay
result
present
mean
percentag
specif
lysi
sd
triplic
sampl
c
releas
assay
cell
isol
dth
sitederiv
cultur
cell
cocultur
nativ
cell
hour
level
cultur
supernat
determin
enzymelink
immunosorb
assay
result
present
mean
sd
triplic
sampl
data
present
result
deriv
patient
treat
aex
plu
granulocytemacrophag
colonystimul
factor
dex
potent
vaccin
tumor
immunotherapi
controversi
conclus
regard
effici
tex
tumor
immunotherapi
drawn
evid
suggest
tex
may
kind
tumor
escap
mechan
induc
toler
host
tumor
antigen
interestingli
immunosuppress
cytokin
includ
tumor
growth
detect
tex
therefor
tex
may
poor
immunogen
clinic
patient
howev
exosom
deriv
malign
effus
melanoma
patient
effici
deliv
melanoma
antigen
autolog
dc
vitro
suggest
aex
may
need
assist
compet
dc
present
antigen
contain
aex
either
mhcantigen
peptid
complex
hspchaperon
antigen
cell
vivo
malign
effus
ascit
use
studi
may
also
contain
dc
cell
methotheli
cell
except
crc
cell
therefor
aex
test
may
mixtur
exosom
deriv
variou
origin
exosom
deriv
differ
origin
similar
morpholog
gradient
densiti
protein
compon
hard
specul
kind
exosom
involv
observ
immun
respons
clinic
outcom
howev
base
previou
studi
detect
cea
aex
cytolog
examin
periton
castoff
cell
data
shown
suggest
major
exosom
deriv
crc
cell
seed
periton
caviti
exosom
deriv
dc
cell
methotheli
cell
may
also
contribut
induct
host
immun
respons
crc
examin
specif
marker
cell
may
help
answer
question
result
previou
work
shown
exosom
prepar
heatstress
ceaposit
tumor
cell
induc
enhanc
hlaa
ceaspecif
ctl
respons
vivo
vitro
exosom
accumul
hsp
mhci
molecul
also
demonstr
other
exosomebas
cancer
vaccin
enhanc
host
immun
respons
tumor
combin
cpg
oligodeoxynucleotid
doublestrand
rna
gmcsf
potenti
properti
vaccin
adjuv
wide
use
adjuv
clinic
trial
cancer
vaccin
gmcsf
factor
mediat
matur
function
dc
increas
express
mhc
molecul
costimul
studi
shown
tumor
cell
either
transfect
gmcsf
gene
mix
gmcsf
biodegrad
capsul
abl
induc
specif
immun
respons
vitro
vivo
studi
select
dose
gmcsf
adjuv
gmcsf
may
enhanc
vaccineinduc
immun
respons
low
dose
rang
suppress
immun
function
higher
dose
therefor
expect
gmcsf
coadministr
aex
may
lead
enhanc
effici
aex
vaccin
promot
antigen
present
tcell
activ
verifi
find
coadministr
aex
gmcsf
superior
aex
alon
induc
hlaa
ceaspecif
ctl
respons
therefor
immunogen
potenti
effici
aex
still
remain
investig
clinic
trial
trial
aex
combin
adjuv
may
improv
effici
aex
crc
immunotherapi
sum
studi
shown
aex
safe
nontox
toler
use
cancer
vaccin
gmcsf
posit
adjuv
induct
antitumor
immun
respons
aexmedi
immunotherapi
studi
may
suggest
aex
combin
gmcsf
may
altern
choic
crc
immunotherapi
futur
character
aex
eg
detect
immunosuppress
cytokin
qualiti
control
exact
cellular
origin
exosom
aex
optim
treatment
plan
greatli
increas
clinic
outcom
aexbas
immunotherapi
patient
phase
clinic
protocol
approv
ethic
committe
institut
review
board
fourth
hospit
affili
guangxi
medic
univers
conduct
complianc
helsinki
declar
elig
patient
fulfil
follow
inclus
criteria
age
year
ii
histolog
diagnosi
crc
iii
eastern
cooper
oncolog
group
perform
statu
iv
hlaa
v
cea
serum
vi
malign
periton
effus
without
hemorrhag
protein
concentr
gl
exclus
criteria
includ
pregnanc
lactat
ii
neutrophil
count
l
platelet
count
l
iii
antihiv
antibodi
ab
iv
activ
infect
v
contraind
leukapheresi
vi
chemotherapi
radiotherapi
undertaken
within
last
week
first
dose
patient
patholog
diagnos
crc
unrespons
reluct
accept
chemotherapi
radiotherapi
primari
ab
use
studi
includ
antihuman
cea
bd
bioscienc
becton
dickinson
ca
ab
mhci
mhcii
santa
cruz
biotechnolog
santa
cruz
ca
horseradish
peroxidasecoupl
secondari
ab
santa
cruz
biotechnolog
human
gmcsf
purchas
scheringplough
china
shanghai
china
roswel
park
memori
institut
fetal
bovin
serum
purchas
hyclon
logan
ut
recombin
human
purchas
sigma
st
loui
mo
human
enzymelink
immunosorb
assay
kit
purchas
r
system
minneapoli
mn
cr
sodium
chromat
purchas
amersham
pharmacia
biotech
arlington
height
il
cea
peptid
coronaviru
sascov
spike
protein
peptid
synthes
gl
biochem
shanghai
china
puriti
phycoerythrinlabel
hlaa
proimmun
oxford
biobusi
centr
littlemor
park
oxford
uk
phycoerythrinlabel
hlaa
kind
gift
dr
x
cao
institut
immunolog
second
militari
medic
univers
pr
china
human
colon
adenocarcinoma
cea
lovo
cea
cell
line
transport
associ
antigen
process
tap
defici
cell
line
obtain
american
type
cultur
collect
manassa
va
maintain
defin
cultur
medium
accord
supplier
specif
aex
prepar
accord
modifi
method
previous
describ
gmp
condit
briefli
ml
malign
ascit
enrol
patient
collect
bag
contain
anticoagul
cell
debri
protein
aggreg
ascit
remov
preliminari
centrifug
centrifug
success
minut
minut
hour
pellet
collect
resuspend
phosphatebuff
salin
pb
centrifug
hour
remov
irrelev
cell
debri
ultracentrifug
sucros
densiti
gradient
hour
aex
contain
sucros
collect
resuspend
pb
ultracentrifug
hour
final
aex
pellet
resuspend
pb
american
societi
gene
therapi
phase
clinic
trial
aex
plu
gmcsf
store
use
aex
determin
protein
concentr
bradford
assay
biorad
endotoxin
exosom
free
confirm
limulu
amebocyt
lysat
assay
electron
microscopi
purifi
aex
fix
hour
paraformaldehyd
wash
pb
pellet
fix
glutaraldehyd
load
formwarcarbonco
em
grid
postfix
glutaraldehyd
contrast
success
uranyl
acet
ph
describ
previous
observ
made
philip
electron
microscopi
eindhoven
netherland
western
blot
analysi
western
blot
done
accord
protocol
describ
previous
us
briefli
amount
aex
whole
cell
lysat
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
gel
transfer
nitrocellulos
membran
incub
specif
primari
ab
supplier
recommend
dilut
final
follow
horseradish
peroxidasecoupl
secondari
ab
chemiluminesc
detect
random
treatment
plan
forti
patient
advanc
crc
enrol
give
written
inform
consent
patient
randomli
assign
eight
group
patient
group
ad
receiv
autolog
aex
pb
subcutan
immun
respect
forearm
patient
group
eg
receiv
autolog
aex
plu
gmcsf
pb
subcutan
immun
respect
forearm
enrol
patient
receiv
total
four
immun
weekli
interv
clinic
monitor
studi
assess
crc
patient
perform
baselin
week
cours
vaccin
day
accord
recist
criteria
tumor
progress
progress
diseas
increas
target
lesion
appear
new
lesion
partial
respons
decreas
target
lesion
complet
respons
disappear
target
tumor
day
first
cours
treatment
toxic
reevalu
treat
physician
respons
therapi
assess
use
criteria
toxic
assess
throughout
studi
use
nation
cancer
institut
common
toxic
criteria
version
analysi
specif
immun
respons
perform
posttreat
dth
reaction
briefli
week
last
vaccin
aex
inject
intraderm
later
limb
vaccin
immun
site
hour
maximum
diamet
millimet
indur
measur
calip
procedur
mainli
follow
modifi
protocol
describ
de
vri
et
al
briefli
punch
biopsi
deriv
posit
dth
site
mm
cut
piec
leukocyt
emigr
tissu
piec
dth
sitederiv
cell
cultur
roswel
park
memori
institut
contain
fetal
bovin
serum
uml
half
medium
replac
fresh
cultur
medium
everi
day
week
cultur
cell
examin
ctl
respons
order
test
specif
releas
evalu
ctl
product
lymphocyt
purifi
use
cellneg
deplet
tetram
test
tetram
test
conduct
accord
previous
describ
method
dth
sitederiv
cell
stain
phycoerythrinlabel
hlaa
tetram
fluorescein
isothiocyanateconjug
minut
room
temperatur
wash
sampl
analyz
flow
cytometri
beckman
epic
xl
specif
releas
assay
conduct
describ
briefli
cell
puls
indic
peptid
use
stimul
cell
lymphocyt
prepar
effector
cell
dth
sitesderiv
cell
effector
cell
stimul
cell
cocultur
micropl
hour
supernat
collect
test
releas
enzymelink
immunosorb
assay
accord
manufactur
protocol
cytotox
assess
cytotox
assess
done
accord
standard
cr
releas
assay
describ
cell
puls
cell
lovo
cell
label
cr
sodium
chromat
triplic
minut
extens
wash
three
time
use
target
cell
effector
cell
dth
sitederiv
cell
cocultur
target
cell
differ
ratio
final
volum
hour
supernat
harvest
measur
chromat
releas
proport
specif
cytotox
determin
accord
formula
countsminut
experiment
cr
releasecountsminut
spontan
cr
releas
countsminut
maxim
cr
releas
countsminut
spontan
cr
releas
count
target
incub
medium
alon
cite
spontan
releas
count
target
incub
triton
cite
maxim
releas
spontan
releas
alway
maxim
releas
result
express
mean
sem
mean
sd
comparison
two
group
conduct
student
ttest
multipl
comparison
done
oneway
analysi
varianc
follow
fisher
least
signific
differ
analysi
pairwis
comparison
done
perform
nonparametr
mannwhitney
u
test
experi
repeat
least
two
time
p
valu
consid
signific
